Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024.

Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.

A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion TherapeuticsAt Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Esperion Contact Information: Investors: Alina Veneziainvestorrelations@esperion.com (734) 887-3903

Media: Tiffany Aldrich corporateteam@esperion.com (616) 443-8438

Grafico Azioni Esperion Therapeutics (NASDAQ:ESPR)
Storico
Da Feb 2025 a Mar 2025 Clicca qui per i Grafici di Esperion Therapeutics
Grafico Azioni Esperion Therapeutics (NASDAQ:ESPR)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Esperion Therapeutics